By DoctoRx : Background : When the Fed noted some froth in "smaller" biotechs last week, large ones also got slammed. Biogen Idec (NASDAQ: BIIB ) fell more than 7% after that statement. Gilead Sciences (NASDAQ: GILD ) fell 5% peak-to-trough. Small ones got dumped big-time. Is it but a passing ...
Vertex Pharmaceuticals ( VRTX ) EVP of Global R&D and Chief Scientific Officer Peter Mueller, Ph.D., announces his retirement effective October 31, 2014, following a planned transition period. Post your comment!
By SA Editor Miriam Metzinger : Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Wednesday July 9. The Four Horsemen of Biotech: Celgene (NASDAQ: CELG ), Regeneron (NASDAQ: REGN ), Biogen Idec (NASDAQ: BIIB ), Gilead (NASDAQ: GILD ) Cramer consulted the technical ...
Vertex Pharmaceuticals ( VRTX +1% ) files an sNDA with the FDA for the approval of Kalydeco (ivacaftor) as a treatment for cystic fibrosis (CF) in patients
Medicinal Products for Human Use (CHMP) recommends that the European Medicines Agency (EMA) approve Vertex Pharmaceuticals ' ( VRTX ) Kalydeco ( ivacaftor ) for cystic fibrosis (CF) patients ages six and older who have one of eight non-G551D
By DoctoRx: Background : Vertex Pharmaceuticals ( VRTX ) is one of a group of biotech/biopharma companies that focuses on oral medications, not injectable proteins. The company has
This morning Vertex Pharmaceutical ( VRTX ) announced positive results for phase ..... with roughly $20 Million in notional on VRTX . As I wrote in my blog post on binary ..... with two unattractive outcomes - if the VRTX clinical trial was successful, the stock
Top 10 Gainers: VRTX +40% . CRMD +33% . XGTI +32% . KONE +32% . NURO +25% . ISR +18% . MEET +17% . UBIC +16% . INWK +12% . SR +12
willing to sell material amounts of stock rather than maintain their shareholdings as long-term investors. Vertex Pharmaceuticals discovers and develops small-molecule drugs for the treatment of serious diseases. The firm's lead drug
June 24 (Reuters) - A combination of Vertex Pharmaceuticals Inc's cystic fibrosis drugs succeeded in improving lung function in a pair of closely watched late-stage trials, likely offering